Table 1.
Questionnaire-based demographic and clinical data of 46 patients with amyotrophic lateral sclerosis (ALS). Data are given either as percentage or median (range)
| Parameter | ALS patients |
|---|---|
| Female, n (%) | 26 (57) |
| Median onset of ALS (years)1 | 62.0 (29–77) |
| Bulbar/Extremity onset | 10/35 |
| Probable/definite ALS | 29/17 |
| Median duration of ALS at examination, range (months) | 19.0 (3–102) |
| Median ALS-FRS-R Score, range | 33.1 (5–45) |
| Assessment of treatment for pain | |
| Patients receiving treatment for pain, n (%) | 17 (37) |
| NSAID, n (%) | 8 (17) |
| Opiates/Opioides, n (%) | 6 (13) |
| Tricyclic antidepressants, n (%) | 0 (0) |
| Katadolone, n (%) | 1 (2) |
| Antiepileptic drugs, n (%) | 3 (6) |
| Specific physiotherapy, n (%) | 2 (4) |
| Assessment of treatment for crampi | |
| Crampi, reported, n (%) | 29 (63) |
| Patients receiving treatment for crampi, n (%) | 12 (26) |
| Treatment with | |
| Magnesium (%) | 12 (26) |
| Chinine sulfate (%) | 2 (4) |
| Pregabaline n (%) | 1 (2) |
| Assessment of treatment for spasticity | |
| Spasticity, in neurological examination, n (%) | 5 (11) |
| Patients receiving treatment for spasticity, n (%) | |
| With baclofen, n (%) | 2 (4) |
| With tolperisone, n (%) | 1 (2) |
ALS-FRS-R revised version of the amyotrophic lateral sclerosis functional rating scale, MRC Medical Research Council, NSAID nonsteroidal anti-inflammatory drugs.
1
Defined as onset of paresis reported by the patient.